Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Vomiting 8Nausea 5Neoplasms 2Lymphoma 2Squamous Cell Carcinoma of Head and Neck 1Radiation Injuries 1Postoperative Nausea and Vomiting 1Post-Dural Puncture Headache 1Multiple Myeloma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 38Carboplatin 28Gemcitabine 23Docetaxel 20Radiotherapy 18Etoposide 15Paclitaxel 13Erlotinib Hydrochloride 13Vinorelbine 11Drug Therapy 11pembrolizumab 9aumolertinib 9apatinib 9Pemetrexed 9Gefitinib 9osimertinib 7endostar protein 7Thoracic Surgery, Video-Assisted 7Blood Specimen Collection 7camrelizumab 6anlotinib 6Vinblastine 6Surgical Procedures, Operative 6sintilimab 5Radiosurgery 5Fluorodeoxyglucose F18 5Cyclophosphamide 5Bevacizumab 5durvalumab 4Mitomycin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lung Neoplasms × Aprepitant × Clear all
NCT02445872 2015-12-09

Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy

Zhejiang University

Phase 2 Unknown
80 enrolled
Thoracic

Lung Neoplasms, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡